EMV Prepares for Trial Following Positive FDA Engagement
Filed with ASX · · 3 pages · English
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- Appendix 4E & Annual Report to 30 June 2024
- First Responder Device Unveiled
- Stage 3 Recuitment Achieved & FDA Engagement Underway
- Pilot Production Line Established & $1.25m Grant Received
- Trial data confirms early ischaemia detection capabilities
Later from EMvision Medical Devices
- Algorithms Deliver Excellent Results In EMView Study
- EMVision Receives $2.12m R&D Tax Rebate
- US Ethics Approval Received for Pivotal Validation Trial
- EMVision Releases its FY25 Half Yearly Report
- S&P DJI Announces March 2025 Quarterly Rebalance
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices